Inteum Company
Links
seedsprint
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - amy+newman
5
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Dopamine D3 Receptor Agonist Compounds, Methods of Preparation, Intermediates Thereof, and their Methods of Use
Abstract: Due to the large degree of homology among dopamine D2-like receptors, discovering ligands capable of discriminating between the D2, D3, and D4 receptor subtypes remains a significant challenge. The development of subtype-selective pharmaceutical small molecules to activate (agonists) signals regulated by D2-like receptors has been especially...
Published: 4/8/2024
|
Inventor(s):
Amy Newman
,
Alessandro Bonifazi
,
Francisco Battiti
,
Sophe Cemaj
Keywords(s):
D3R agonists
,
Dopamine
,
Newman
,
Parkinson’s Disease
,
Restless Legs Syndrome
,
RLS
,
small molecule
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
Application > Therapeutics
,
TherapeuticArea > Neurology
Analogues of Modafinil for treating sleep and attention disorders
Abstract: Modafinil has attracted attention for the treatment of cognitive dysfunction in disorders such as attention-deficit/hyperactivity disorder (ADHD) as well as cocaine and methamphetamine dependence. However, modafinil has relatively low affinity for binding to the dopamine transporter (DAT) to block dopamine reuptake, and is water-insoluble,...
Published: 4/8/2024
|
Inventor(s):
Amy Newman
,
Oluyomi Okunola-Bakare
,
Jianjing Cao
Keywords(s):
attention deficit/hyperactivity disorder (ADHD)
,
dopamine (DAT)
,
Modafinil
,
Narcolepsy
,
norepinephrine (NET)
,
serotonin (SERT)
Category(s):
Application > Therapeutics
,
Collaboration Sought > Licensing
Methods of making and using dopamine receptor selective antagonists/partial agonists
Abstract: Dopamine is a major neurotransmitter in the central nervous system and among other functions is directly related to the rewarding effects of drugs of abuse. Dopamine signaling is mediated by D1, D2, D3, D4 and D5 receptors. The dopamine D3 receptor is a known target to treat a variety of neuropsychiatric disorders, including substance use...
Published: 4/8/2024
|
Inventor(s):
Amy Newman
,
Vivek Kumar
,
Anverbasha Shaik
Keywords(s):
Bipolar Disorder
,
Cannabis
,
DEPENDENCE
,
dopamine D3 receptor
,
drug addiction
,
oxycodone
,
SCHIZOPHRENIA
Category(s):
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
TherapeuticArea > Neurology
,
Application > Therapeutics
Atypical Inhibitors of Monoamine Transporters; Method of Making; and Use Thereof
Abstract: Substance use disorder is a chronic medical condition, taking its toll on our public health care and judicial systems in an economically unsustainable way. More than 20 million Americans suffer from substance use disorders. Certainly, the development of prevention and treatment options as alternatives to incarceration is the appropriate and...
Published: 4/8/2024
|
Inventor(s):
Amy Newman
,
JoLynn Giancola
,
Rachel Slack
,
Jianjing Cao
Keywords(s):
ADHD
,
dopamine reuptake inhibitor
,
Newman
,
sleep disorders
,
Substance use disorder
Category(s):
Application > Therapeutics
,
Collaboration Sought > Collaboration
,
Collaboration Sought > Licensing
,
TherapeuticArea > Neurology
Novel Dopamine Receptor Ligands As Therapeutics For Central Nervous System Disorders
Abstract: The National Institute on Drug Abuse's Medications Discovery Research Branch is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize 4-phenylpiperazine derivatives as dopamine D3 selective ligands. The dopamine D3 receptor subtype is a member of the dopamine...
Published: 4/8/2024
|
Inventor(s):
Amy Newman
,
Peter Grundt
,
Jianjing Cao
,
Robert Luedtke
,
George Cyriac
Keywords(s):
Category(s):
Application > Research Materials
,
TherapeuticArea > Gastroenterology
,
Collaboration Sought > Licensing